United Therapeutics
UTHR
332 hedge funds and large institutions have $4.26B invested in United Therapeutics in 2020 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 121 increasing their positions, 120 reducing their positions, and 58 closing their positions.
120% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $5.86M
1% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 120
1.27% less ownership
Funds ownership: 96.3% → 95.03% (-1.3%)
5% less funds holding
Funds holding: 349 → 332 (-17)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
17% less capital invested
Capital invested by funds: $5.13B → $4.26B (-$863M)
26% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$24.5M |
| 2 |
Goldman Sachs
New York
|
+$21.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.8M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$18.5M |
| 5 |
D.E. Shaw & Co
New York
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$42.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27.5M |
| 3 |
BlackRock
New York
|
-$23.6M |
| 4 |
Two Sigma Investments
New York
|
-$19.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.2M |
UTHR Hedge Fund Activity: Q3 2020 in Review
332 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2020, worth a combined $4.26B — down 17% from $5.13B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of UTHR and 43 opened new positions — a net loss of 15 holders — while 120 trimmed existing stakes and 121 added.
The largest buyer was First Trust Advisors, adding an estimated $24.5M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $42.4M sold.
- 332 institutional investors held United Therapeutics (UTHR) as of Q3 2020, down from 349 in Q2 2020.
- Funds reported $4.26B of United Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
- 43 funds opened new United Therapeutics positions in Q3 2020 and 58 closed out, a net change of -15 holders.
- The largest United Therapeutics buyer in Q3 2020 was First Trust Advisors, an estimated $24.5M added.
- The largest United Therapeutics seller in Q3 2020 was Farallon Capital Management, an estimated $42.4M sold.
Based on aggregated 13F filings for Q3 2020.